EMD Serono is an emerging oncology company in the United States. EMD Serono’s diversified Oncology and Immuno-Oncology pipeline includes multiple, high-priority projects currently in development to optimize patient outcomes in challenging cancers that have significant unmet patient need. Our dedicated R&D translational innovation platforms are focused on using emerging science and tools to apply the principles of Precision Medicine to develop personalized therapies that may optimize treatment outcomes for patients.
Leveraging a Strong Global Heritage
As part of the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, we are uniquely positioned to draw from the resources and experiences of our parent company in the area of oncology. In the US, we aim to continue our strong legacy of bringing best-in-class products and solutions to patients as we move into oncology, where we already have an alliance with Pfizer to co-promote their lung cancer therapy.